104 related articles for article (PubMed ID: 18641620)
1. Turning down tau phosphorylation.
Fischer PM
Nat Chem Biol; 2008 Aug; 4(8):448-9. PubMed ID: 18641620
[TBL] [Abstract][Full Text] [Related]
2. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
3. Following the leader: fibrillization of alpha-synuclein and tau.
Frasier M; Wolozin B
Exp Neurol; 2004 Jun; 187(2):235-9. PubMed ID: 15144849
[No Abstract] [Full Text] [Related]
4. Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.
Sahara N; Maeda S; Yoshiike Y; Mizoroki T; Yamashita S; Murayama M; Park JM; Saito Y; Murayama S; Takashima A
J Neurosci Res; 2007 Nov; 85(14):3098-108. PubMed ID: 17628496
[TBL] [Abstract][Full Text] [Related]
5. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.
Höllerhage M; Matusch A; Champy P; Lombès A; Ruberg M; Oertel WH; Höglinger GU
Exp Neurol; 2009 Nov; 220(1):133-42. PubMed ID: 19682988
[TBL] [Abstract][Full Text] [Related]
6. Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains.
Sasaki K; Shimura H; Itaya M; Tanaka R; Mori H; Mizuno Y; Kosik KS; Tanaka S; Hattori N
FEBS Lett; 2009 Jul; 583(13):2194-200. PubMed ID: 19527721
[TBL] [Abstract][Full Text] [Related]
7. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N; Korenova M; Novak M
Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
[TBL] [Abstract][Full Text] [Related]
8. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
9. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells.
Pickhardt M; Larbig G; Khlistunova I; Coksezen A; Meyer B; Mandelkow EM; Schmidt B; Mandelkow E
Biochemistry; 2007 Sep; 46(35):10016-23. PubMed ID: 17685560
[TBL] [Abstract][Full Text] [Related]
10. Prospect of therapeutic approaches to tauopathies.
Roder HM
J Mol Neurosci; 2003 Apr; 20(2):195-202. PubMed ID: 12794313
[TBL] [Abstract][Full Text] [Related]
11. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
12. Pathological tau: a loss of normal function or a gain in toxicity?
Trojanowski JQ; Lee VM
Nat Neurosci; 2005 Sep; 8(9):1136-7. PubMed ID: 16127446
[No Abstract] [Full Text] [Related]
13. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
[TBL] [Abstract][Full Text] [Related]
14. Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein.
Sadik G; Tanaka T; Kato K; Yanagi K; Kudo T; Takeda M
Biochem Biophys Res Commun; 2009 May; 383(1):37-41. PubMed ID: 19324008
[TBL] [Abstract][Full Text] [Related]
15. [The role of lithium in neurodegenerative diseases: new registries for old actors].
Pérez-Martínez DA
Neurologia; 2009 Apr; 24(3):143-6. PubMed ID: 19418288
[TBL] [Abstract][Full Text] [Related]
16. Sugar Kick Prevents Memory Impairment.
Rudrawar S; Ryan P
J Med Chem; 2019 Nov; 62(22):10059-10061. PubMed ID: 31668062
[TBL] [Abstract][Full Text] [Related]
17. Substrate-specific reduction of PP2A activity exaggerates tau pathology.
Deters N; Ittner LM; Götz J
Biochem Biophys Res Commun; 2009 Feb; 379(2):400-5. PubMed ID: 19126401
[TBL] [Abstract][Full Text] [Related]
18. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
Yuzwa SA; Macauley MS; Heinonen JE; Shan X; Dennis RJ; He Y; Whitworth GE; Stubbs KA; McEachern EJ; Davies GJ; Vocadlo DJ
Nat Chem Biol; 2008 Aug; 4(8):483-90. PubMed ID: 18587388
[TBL] [Abstract][Full Text] [Related]
19. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
[TBL] [Abstract][Full Text] [Related]
20. [Structure and role of the tau protein].
Baksalerska-Pazera M; Niewiadomska G
Postepy Biochem; 2002; 48(4):287-95. PubMed ID: 12731394
[No Abstract] [Full Text] [Related]
[Next] [New Search]
